WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc., a privately held medical device and pharmaceutical company, today announced A. John Kanellopoulos, MD has been named to its Medical Advisory Board. Dr. Kanellopoulos is a Clinical Professor of Ophthalmology at the NYU School of Medicine and Director of the Laser Vision Institute, Athens, Greece.
A recognized leader in the science and clinical application of corneal cross-linking, Dr. Kanellopoulos developed the Athens protocol for keratoconus and ectasia (combined topography-guided excimer laser normalization of the irregular cornea and cross-linking), clinically introduced the concept of higher fluence cross-linking, and also introduced prophylactic cross-linking with Lasik, a precursor to Avedro’s Lasik Xtra procedure. At five years follow up, he has found that corneas treated with the Athens Protocol continue to remain stable. Dr. Kanellopoulos’ research has also determined that collagen cross- linking may be beneficial for infectious keratitis, corneal melts and pseudophakic keratopathy.
“As we learn more about the way we perform corneal cross-linking, it is going to become a pivotal tool in manipulating corneal biomechanics,” says Dr. Kanellopoulos. “I am delighted to join the Avedro team and help to bring corneal cross-linking to the next level.”
"We are privileged to welcome Dr. Kanellopoulos to our Medical Advisory Board,” commented David Muller, PhD, CEO of Avedro. “John is a prolific researcher and superb refractive surgeon who will be a valuable asset as we continue to set the standard in the science of corneal cross-linking and corneal biomechanics.”
Dr. Kanellopoulos will be honored at the 2011 American Academy of Ophthalmology meeting with the prestigious Lans Distinguished Award. The Lans Distinguished Award recognizes an individual who is an innovative researcher in the field of refractive surgery.
About Laser Vision.gr Institute for Laser
LaserVision.gr was founded in August 2001 as a pioneering ophthalmology reference center with a scientific radius extending internationally. Its medical and scientific teams participate extensively in international ophthalmic congresses as well as personally organizing numerous clinical seminars to train colleagues in the use of its advanced methods. In its effort to provide patients with the most advanced healthcare services, the LaserVision.gr team strives to remain on top of research developments and the application of new technologies in ophthalmology.
The LaserVision.gr clinic occupies an area of over 20,000 square feet, which include 12 examination rooms, 4 operating theaters, extensive waiting areas, and meeting rooms, all characterized by the highest aesthetics and functionality. It has been accredited with the strenuous parameters of European ISO 2008, as a clinical, research and surgical ophthalmological center since 2010.
About Avedro, Inc.
Avedro is a privately held medical device and pharmaceutical company advancing the science of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and post-lasik ectasia and has received orphan drug designation from the FDA for its VibeX™ brand of riboflavin. Outside the United States, Avedro has commercialized both VibeX and its KXL™ System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with LASIK and other refractive correction procedures. Keraflex is commercially available outside of the United States.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50027715&lang=en